HEADER SIGNALING PROTEIN 29-JUL-15 5AAV TITLE OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-(3,5-DIFLUORO-4- TITLE 2 ((1R,3R)-2-(2-FLUORO-2-METHYLPROPYL)-3-METHYL-2,3,4,9-TETRAHYDRO-1H- TITLE 3 PYRIDO(3,4-B)INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496), A POTENT AND TITLE 4 ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR AND TITLE 5 ANTAGONIST COMPND MOL_ID: 1; COMPND 2 MOLECULE: ESTROGEN RECEPTOR; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: LIGAND-BINDING DOMAIN; COMPND 5 SYNONYM: ER, ER-ALPHA, ESTRADIOL RECEPTOR, NUCLEAR RECEPTOR SUBFAMILY COMPND 6 3 GROUP A MEMBER 1, ESTROGEN RECEPTOR ALPHA; COMPND 7 ENGINEERED: YES; COMPND 8 MUTATION: YES; COMPND 9 MOL_ID: 2; COMPND 10 MOLECULE: ESTROGEN RECEPTOR; COMPND 11 CHAIN: B; COMPND 12 FRAGMENT: LIGAND-BINDING DOMAIN; COMPND 13 SYNONYM: ER, ER-ALPHA, ESTRADIOL RECEPTOR, NUCLEAR RECEPTOR SUBFAMILY COMPND 14 3 GROUP A MEMBER 1, ESTROGEN RECEPTOR ALPHA; COMPND 15 ENGINEERED: YES; COMPND 16 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_VARIANT: GOLD; SOURCE 9 MOL_ID: 2; SOURCE 10 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 11 ORGANISM_COMMON: HUMAN; SOURCE 12 ORGANISM_TAXID: 9606; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 15 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 16 EXPRESSION_SYSTEM_VARIANT: GOLD KEYWDS SIGNALING PROTEIN, BREAST CANCER, ESTROGEN RECEPTOR DOWNREGULATOR, KEYWDS 2 FULVESTRANT, AZD9496, NUCLEAR HORMONE RECEPTOR EXPDTA X-RAY DIFFRACTION AUTHOR R.A.NORMAN,R.H.BRADBURY,C.DE ALMEIDA,D.M.ANDREWS,P.BALLARD,D.BUTTAR, AUTHOR 2 R.J.CALLIS,G.S.CURRIE,J.O.CURWEN,C.D.DAVIES,C.DE SAVI,C.S.DONALD, AUTHOR 3 L.J.L.FERON,S.C.GLOSSOP,B.R.HAYTER,G.KAROUTCHI,S.G.LAMONT,P.MACFAUL, AUTHOR 4 T.MOSS,S.E.PEARSON,A.A.RABOW,M.TONGE,G.E.WALKER,H.M.WEIR,Z.WILSON REVDAT 4 01-MAY-24 5AAV 1 REMARK HETSYN REVDAT 3 12-OCT-16 5AAV 1 REMARK REVDAT 2 04-NOV-15 5AAV 1 JRNL REVDAT 1 14-OCT-15 5AAV 0 JRNL AUTH C.DE SAVI,R.H.BRADBURY,A.A.RABOW,R.A.NORMAN,C.DE ALMEIDA, JRNL AUTH 2 D.M.ANDREWS,P.BALLARD,D.BUTTAR,R.CALLIS,G.S.CURRIE,C.DAVIES, JRNL AUTH 3 C.DONALD,L.FERON,B.R.HAYTER,S.HUSSAIN,G.KAROUTCHI,S.LAMONT, JRNL AUTH 4 P.A.MACFAUL,T.A.MOSS,S.PEARSON,M.TONGE,G.WALKER,H.WEIR, JRNL AUTH 5 Z.WILSON JRNL TITL OPTIMIZATION OF A NOVEL BINDING MOTIF TO JRNL TITL 2 (E)-3-(3,5-DIFLUORO-4-((1R,3R)-2-(2-FLUORO-2-METHYLPROPYL) JRNL TITL 3 -3-METHYL-2, JRNL TITL 4 3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOL-1-YL)PHENYL)ACRYLIC JRNL TITL 5 ACID (AZD9496), A POTENT AND ORALLY BIOAVAILABLE SELECTIVE JRNL TITL 6 ESTROGEN RECEPTOR DOWNREGULATOR AND ANTAGONIST. JRNL REF J.MED.CHEM. V. 58 8128 2015 JRNL REFN ISSN 0022-2623 JRNL PMID 26407012 JRNL DOI 10.1021/ACS.JMEDCHEM.5B00984 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH H.M.WEIR,R.H.BRADBURY,M.LAWSON,A.A.RABOW,D.BUTTAR, REMARK 1 AUTH 2 R.J.CALLIS,J.O.CURWEN,C.DE ALMEIDA,P.BALLARD,M.HULSE, REMARK 1 AUTH 3 C.S.DONALD,L.J.L.FERON,G.KAROUTCHI,P.MACFAUL,T.MOSS, REMARK 1 AUTH 4 R.A.NORMAN,S.E.PEARSON,M.TONGE,G.DAVIES,G.E.WALKER,Z.WILSON, REMARK 1 AUTH 5 R.ROWLINSON,S.POWELL,C.SADLER,G.RICHMOND,B.LADD,E.PAZOLLI, REMARK 1 AUTH 6 A.M.MAZZOLA,C.D'CRUZ,C.DE SAVI REMARK 1 TITL AZD9496: AN ORAL ESTROGEN RECEPTOR INHIBITOR THAT BLOCKS THE REMARK 1 TITL 2 GROWTH OF ER-POSITIVE AND ESR1-MUTANT BREAST TUMORS IN REMARK 1 TITL 3 PRECLINICAL MODELS. REMARK 1 REF CANCER RES. V. 76 3307 2016 REMARK 1 REFN ISSN 0008-5472 REMARK 1 PMID 27020862 REMARK 1 DOI 10.1158/0008-5472.CAN-15-2357 REMARK 2 REMARK 2 RESOLUTION. 1.95 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.8.0103 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.95 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 44.32 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 98.8 REMARK 3 NUMBER OF REFLECTIONS : 30991 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.198 REMARK 3 R VALUE (WORKING SET) : 0.196 REMARK 3 FREE R VALUE : 0.234 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 1653 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.95 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.00 REMARK 3 REFLECTION IN BIN (WORKING SET) : 2287 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.92 REMARK 3 BIN R VALUE (WORKING SET) : 0.2260 REMARK 3 BIN FREE R VALUE SET COUNT : 125 REMARK 3 BIN FREE R VALUE : 0.2700 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3413 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 54 REMARK 3 SOLVENT ATOMS : 166 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 28.49 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 0.08000 REMARK 3 B22 (A**2) : 0.12000 REMARK 3 B33 (A**2) : -0.20000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.03000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.185 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.160 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.115 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 8.947 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.944 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.919 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 3565 ; 0.010 ; 0.019 REMARK 3 BOND LENGTHS OTHERS (A): 3458 ; 0.002 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 4831 ; 1.370 ; 1.989 REMARK 3 BOND ANGLES OTHERS (DEGREES): 7904 ; 0.944 ; 3.000 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 442 ; 5.197 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 140 ;37.887 ;23.857 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 625 ;13.895 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 18 ;14.693 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 573 ; 0.073 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 3935 ; 0.005 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): 781 ; 0.001 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1765 ; 1.150 ; 2.513 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): 1764 ; 1.150 ; 2.511 REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2193 ; 1.970 ; 3.738 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1800 ; 1.248 ; 2.614 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 1 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 303 A 551 REMARK 3 ORIGIN FOR THE GROUP (A): 40.4427 0.4590 22.4125 REMARK 3 T TENSOR REMARK 3 T11: 0.0343 T22: 0.0269 REMARK 3 T33: 0.0534 T12: 0.0248 REMARK 3 T13: -0.0038 T23: -0.0033 REMARK 3 L TENSOR REMARK 3 L11: 0.4330 L22: 0.2444 REMARK 3 L33: 0.3522 L12: -0.3083 REMARK 3 L13: -0.0450 L23: 0.1121 REMARK 3 S TENSOR REMARK 3 S11: 0.0475 S12: -0.0137 S13: 0.0447 REMARK 3 S21: -0.0216 S22: 0.0163 S23: -0.0292 REMARK 3 S31: 0.0565 S32: 0.0367 S33: -0.0638 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS. U VALUES WITH TLS ADDED REMARK 4 REMARK 4 5AAV COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 29-JUL-15. REMARK 100 THE DEPOSITION ID IS D_1290064536. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : DIAMOND REMARK 200 BEAMLINE : I04 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.96 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : PIXEL REMARK 200 DETECTOR MANUFACTURER : DECTRIS PILATUS 6M REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 30991 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.950 REMARK 200 RESOLUTION RANGE LOW (A) : 52.700 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.0 REMARK 200 DATA REDUNDANCY : 6.400 REMARK 200 R MERGE (I) : 0.10000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 16.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.95 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.06 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.9 REMARK 200 DATA REDUNDANCY IN SHELL : 6.50 REMARK 200 R MERGE FOR SHELL (I) : 0.37000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 4.700 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: IN HOUSE MODEL REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 39.22 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.02 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.1 M PCTP, PH 6.5 (0.04 M SODIUM REMARK 280 PROPIONATE, 0.02 M SODIUM CACODYLATE, 0.04 M BIS-TRIS PROPANE), REMARK 280 22% PEG3350, 0.2M MGCL2 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: C 1 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y,-Z REMARK 290 3555 X+1/2,Y+1/2,Z REMARK 290 4555 -X+1/2,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 3 1.000000 0.000000 0.000000 52.74400 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 25.77000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 52.74400 REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 25.77000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4300 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 19470 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -1.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 LYS A 416 REMARK 465 SER A 417 REMARK 465 VAL A 418 REMARK 465 GLU A 419 REMARK 465 GLY A 420 REMARK 465 LEU A 462 REMARK 465 SER A 463 REMARK 465 SER A 464 REMARK 465 THR A 465 REMARK 465 LEU A 466 REMARK 465 LYS A 467 REMARK 465 SER A 468 REMARK 465 LEU A 469 REMARK 465 LYS A 529 REMARK 465 SER A 530 REMARK 465 LYS A 531 REMARK 465 ASN A 532 REMARK 465 PRO A 552 REMARK 465 THR A 553 REMARK 465 SER A 554 REMARK 465 GLY B 303 REMARK 465 SER B 304 REMARK 465 HIS B 305 REMARK 465 TYR B 331 REMARK 465 ASP B 332 REMARK 465 PRO B 333 REMARK 465 THR B 334 REMARK 465 VAL B 418 REMARK 465 GLU B 419 REMARK 465 GLY B 420 REMARK 465 VAL B 458 REMARK 465 TYR B 459 REMARK 465 THR B 460 REMARK 465 PHE B 461 REMARK 465 LEU B 462 REMARK 465 SER B 463 REMARK 465 SER B 464 REMARK 465 THR B 465 REMARK 465 LEU B 466 REMARK 465 LYS B 467 REMARK 465 SER B 468 REMARK 465 LEU B 469 REMARK 465 GLU B 470 REMARK 465 GLU B 471 REMARK 465 SER B 527 REMARK 465 MET B 528 REMARK 465 LYS B 529 REMARK 465 SER B 530 REMARK 465 LYS B 531 REMARK 465 ASN B 532 REMARK 465 VAL B 533 REMARK 465 VAL B 534 REMARK 465 PRO B 535 REMARK 465 SER B 536 REMARK 465 ALA B 546 REMARK 465 HIS B 547 REMARK 465 ARG B 548 REMARK 465 LEU B 549 REMARK 465 HIS B 550 REMARK 465 ALA B 551 REMARK 465 PRO B 552 REMARK 465 THR B 553 REMARK 465 SER B 554 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 339 CG CD OE1 OE2 REMARK 470 GLU A 380 CD OE1 OE2 REMARK 470 GLU A 397 CD OE1 OE2 REMARK 470 GLU A 423 CG CD OE1 OE2 REMARK 470 ARG A 434 CG CD NE CZ NH1 NH2 REMARK 470 PHE A 461 CG CD1 CD2 CE1 CE2 CZ REMARK 470 GLU A 470 CG CD OE1 OE2 REMARK 470 GLU A 471 CG CD OE1 OE2 REMARK 470 LYS A 472 CG CD CE NZ REMARK 470 LYS A 520 CE NZ REMARK 470 LEU B 308 CG CD1 CD2 REMARK 470 ARG B 335 CG CD NE CZ NH1 NH2 REMARK 470 GLU B 339 CG CD OE1 OE2 REMARK 470 MET B 342 CG SD CE REMARK 470 ASN B 359 CG OD1 ND2 REMARK 470 LYS B 362 CD CE NZ REMARK 470 GLU B 380 CG CD OE1 OE2 REMARK 470 ARG B 412 CG CD NE CZ NH1 NH2 REMARK 470 ASN B 413 CG OD1 ND2 REMARK 470 LYS B 416 CG CD CE NZ REMARK 470 GLU B 423 CG CD OE1 OE2 REMARK 470 MET B 437 CG SD CE REMARK 470 ASN B 439 CG OD1 ND2 REMARK 470 LYS B 472 CG CD CE NZ REMARK 470 HIS B 476 CG ND1 CD2 CE1 NE2 REMARK 470 TYR B 526 CG CD1 CD2 CE1 CE2 CZ OH REMARK 470 TYR B 537 CG CD1 CD2 CE1 CE2 CZ OH REMARK 470 GLU B 542 CG CD OE1 OE2 REMARK 470 MET B 543 CG SD CE REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 ND2 ASN A 359 OH TYR B 328 3455 1.98 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 332 70.80 -157.22 REMARK 500 SER A 338 170.04 -54.57 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GW5 A 1552 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GW5 B 1546 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 5AAU RELATED DB: PDB REMARK 900 OPTIMIZATION OF A NOVEL BINDING MOTIF TO TO (E)-3-( 3,5-DIFLUORO-4- REMARK 900 ((1R,3R)-2-(2-FLUORO-2-METHYLPROPYL )-3-METHYL-2,3,4,9-TETRAHYDRO- REMARK 900 1H-PYRIDO(3,4-B) INDOL-1-YL)PHENYL)ACRYLIC ACID (AZD9496), A POTENT REMARK 900 AND ORALLY BIOAVAILABLE SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR REMARK 900 AND ANTAGONIST DBREF 5AAV A 307 554 UNP P03372 ESR1_HUMAN 307 554 DBREF 5AAV B 306 554 UNP P03372 ESR1_HUMAN 306 554 SEQADV 5AAV GLY A 303 UNP P03372 EXPRESSION TAG SEQADV 5AAV SER A 304 UNP P03372 EXPRESSION TAG SEQADV 5AAV HIS A 305 UNP P03372 EXPRESSION TAG SEQADV 5AAV MET A 306 UNP P03372 EXPRESSION TAG SEQADV 5AAV SER A 381 UNP P03372 CYS 381 ENGINEERED MUTATION SEQADV 5AAV SER A 417 UNP P03372 CYS 417 ENGINEERED MUTATION SEQADV 5AAV SER A 530 UNP P03372 CYS 530 ENGINEERED MUTATION SEQADV 5AAV SER A 536 UNP P03372 LEU 536 ENGINEERED MUTATION SEQADV 5AAV GLY B 303 UNP P03372 EXPRESSION TAG SEQADV 5AAV SER B 304 UNP P03372 EXPRESSION TAG SEQADV 5AAV HIS B 305 UNP P03372 EXPRESSION TAG SEQADV 5AAV SER B 381 UNP P03372 CYS 381 ENGINEERED MUTATION SEQADV 5AAV SER B 417 UNP P03372 CYS 417 ENGINEERED MUTATION SEQADV 5AAV SER B 530 UNP P03372 CYS 530 ENGINEERED MUTATION SEQADV 5AAV SER B 536 UNP P03372 LEU 536 ENGINEERED MUTATION SEQRES 1 A 252 GLY SER HIS MET ALA LEU SER LEU THR ALA ASP GLN MET SEQRES 2 A 252 VAL SER ALA LEU LEU ASP ALA GLU PRO PRO ILE LEU TYR SEQRES 3 A 252 SER GLU TYR ASP PRO THR ARG PRO PHE SER GLU ALA SER SEQRES 4 A 252 MET MET GLY LEU LEU THR ASN LEU ALA ASP ARG GLU LEU SEQRES 5 A 252 VAL HIS MET ILE ASN TRP ALA LYS ARG VAL PRO GLY PHE SEQRES 6 A 252 VAL ASP LEU THR LEU HIS ASP GLN VAL HIS LEU LEU GLU SEQRES 7 A 252 SER ALA TRP LEU GLU ILE LEU MET ILE GLY LEU VAL TRP SEQRES 8 A 252 ARG SER MET GLU HIS PRO GLY LYS LEU LEU PHE ALA PRO SEQRES 9 A 252 ASN LEU LEU LEU ASP ARG ASN GLN GLY LYS SER VAL GLU SEQRES 10 A 252 GLY MET VAL GLU ILE PHE ASP MET LEU LEU ALA THR SER SEQRES 11 A 252 SER ARG PHE ARG MET MET ASN LEU GLN GLY GLU GLU PHE SEQRES 12 A 252 VAL CYS LEU LYS SER ILE ILE LEU LEU ASN SER GLY VAL SEQRES 13 A 252 TYR THR PHE LEU SER SER THR LEU LYS SER LEU GLU GLU SEQRES 14 A 252 LYS ASP HIS ILE HIS ARG VAL LEU ASP LYS ILE THR ASP SEQRES 15 A 252 THR LEU ILE HIS LEU MET ALA LYS ALA GLY LEU THR LEU SEQRES 16 A 252 GLN GLN GLN HIS GLN ARG LEU ALA GLN LEU LEU LEU ILE SEQRES 17 A 252 LEU SER HIS ILE ARG HIS MET SER ASN LYS GLY MET GLU SEQRES 18 A 252 HIS LEU TYR SER MET LYS SER LYS ASN VAL VAL PRO SER SEQRES 19 A 252 TYR ASP LEU LEU LEU GLU MET LEU ASP ALA HIS ARG LEU SEQRES 20 A 252 HIS ALA PRO THR SER SEQRES 1 B 252 GLY SER HIS LEU ALA LEU SER LEU THR ALA ASP GLN MET SEQRES 2 B 252 VAL SER ALA LEU LEU ASP ALA GLU PRO PRO ILE LEU TYR SEQRES 3 B 252 SER GLU TYR ASP PRO THR ARG PRO PHE SER GLU ALA SER SEQRES 4 B 252 MET MET GLY LEU LEU THR ASN LEU ALA ASP ARG GLU LEU SEQRES 5 B 252 VAL HIS MET ILE ASN TRP ALA LYS ARG VAL PRO GLY PHE SEQRES 6 B 252 VAL ASP LEU THR LEU HIS ASP GLN VAL HIS LEU LEU GLU SEQRES 7 B 252 SER ALA TRP LEU GLU ILE LEU MET ILE GLY LEU VAL TRP SEQRES 8 B 252 ARG SER MET GLU HIS PRO GLY LYS LEU LEU PHE ALA PRO SEQRES 9 B 252 ASN LEU LEU LEU ASP ARG ASN GLN GLY LYS SER VAL GLU SEQRES 10 B 252 GLY MET VAL GLU ILE PHE ASP MET LEU LEU ALA THR SER SEQRES 11 B 252 SER ARG PHE ARG MET MET ASN LEU GLN GLY GLU GLU PHE SEQRES 12 B 252 VAL CYS LEU LYS SER ILE ILE LEU LEU ASN SER GLY VAL SEQRES 13 B 252 TYR THR PHE LEU SER SER THR LEU LYS SER LEU GLU GLU SEQRES 14 B 252 LYS ASP HIS ILE HIS ARG VAL LEU ASP LYS ILE THR ASP SEQRES 15 B 252 THR LEU ILE HIS LEU MET ALA LYS ALA GLY LEU THR LEU SEQRES 16 B 252 GLN GLN GLN HIS GLN ARG LEU ALA GLN LEU LEU LEU ILE SEQRES 17 B 252 LEU SER HIS ILE ARG HIS MET SER ASN LYS GLY MET GLU SEQRES 18 B 252 HIS LEU TYR SER MET LYS SER LYS ASN VAL VAL PRO SER SEQRES 19 B 252 TYR ASP LEU LEU LEU GLU MET LEU ASP ALA HIS ARG LEU SEQRES 20 B 252 HIS ALA PRO THR SER HET GW5 A1552 27 HET GW5 B1546 27 HETNAM GW5 (2E)-3-{4-[(1E)-1,2-DIPHENYLBUT-1-ENYL]PHENYL}ACRYLIC HETNAM 2 GW5 ACID HETSYN GW5 GW5638; DPC 974 FORMUL 3 GW5 2(C25 H22 O2) FORMUL 5 HOH *166(H2 O) HELIX 1 1 MET A 306 LEU A 310 5 5 HELIX 2 2 THR A 311 GLU A 323 1 13 HELIX 3 3 SER A 338 ARG A 363 1 26 HELIX 4 4 GLY A 366 LEU A 370 5 5 HELIX 5 5 THR A 371 SER A 395 1 25 HELIX 6 6 GLU A 423 ASN A 439 1 17 HELIX 7 7 GLN A 441 SER A 456 1 16 HELIX 8 8 GLU A 470 ALA A 493 1 24 HELIX 9 9 THR A 496 MET A 528 1 33 HELIX 10 10 SER A 536 HIS A 547 1 12 HELIX 11 11 ARG A 548 HIS A 550 5 3 HELIX 12 12 LEU B 306 LEU B 310 5 5 HELIX 13 13 THR B 311 GLU B 323 1 13 HELIX 14 14 SER B 338 ARG B 363 1 26 HELIX 15 15 THR B 371 MET B 396 1 26 HELIX 16 16 ARG B 412 LYS B 416 1 5 HELIX 17 17 MET B 421 ASN B 439 1 19 HELIX 18 18 GLN B 441 SER B 456 1 16 HELIX 19 19 LYS B 472 ALA B 493 1 22 HELIX 20 20 THR B 496 TYR B 526 1 31 HELIX 21 21 TYR B 537 ASP B 545 1 9 SHEET 1 AA 2 LYS A 401 ALA A 405 0 SHEET 2 AA 2 LEU A 408 ASP A 411 -1 O LEU A 408 N PHE A 404 SHEET 1 BA 2 LYS B 401 ALA B 405 0 SHEET 2 BA 2 LEU B 408 ASP B 411 -1 O LEU B 408 N PHE B 404 SITE 1 AC1 7 LEU A 346 THR A 347 ALA A 350 GLU A 353 SITE 2 AC1 7 LEU A 428 GLY A 521 PRO A 535 SITE 1 AC2 7 MET B 343 LEU B 346 THR B 347 ALA B 350 SITE 2 AC2 7 GLU B 353 LEU B 428 GLY B 521 CRYST1 105.488 51.540 83.705 90.00 90.90 90.00 C 1 2 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.009480 0.000000 0.000149 0.00000 SCALE2 0.000000 0.019402 0.000000 0.00000 SCALE3 0.000000 0.000000 0.011948 0.00000